NewAmsterdam Pharma Company N.V (NAMS) Stock Analysis
Falling Knife setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $30.57: Quality below floor (3.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10 and A.R:R 3.7:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 2.20; Below-average business quality; Negative price momentum.
NewAmsterdam Pharma is a clinical-stage biopharmaceutical company developing obicetrapib, an oral CETP inhibitor for LDL-C lowering in cardiovascular disease patients. The company has no approved products and generates no product revenue; it is funded through equity and operates... Read more
Sell if holding. Engine safety override at $30.57: Quality below floor (3.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10 and A.R:R 3.7:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 2.20; Below-average business quality; Negative price momentum. Chart setup: Death cross, below all MAs, RSI 24, MACD bearish. Score 5.2/10, moderate confidence.
Passes 6/8 gates (favorable risk/reward ratio, clean insider activity, news events none recent, earnings proximity 51d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.
About NewAmsterdam Pharma Company N.V
About NewAmsterdam Pharma Company N.V
NewAmsterdam Pharma's entire value proposition rests on a single compound: obicetrapib, an oral CETP inhibitor targeting LDL-C reduction in patients with ASCVD and/or HeFH. Three pivotal Phase 3 trials completed between July 2024 and November 2024—BROADWAY (over 2,500 randomized patients), BROOKLYN (over 350 patients), and TANDEM—each met their primary endpoints. The company reported a net loss of $203.8 million for the year ended December 31, 2025, with an accumulated deficit of $762.4 million and $728.9 million in cash and marketable securities.
NewAmsterdam Pharma generates no product revenue; all operations are funded through equity and debt. The company has partnered with Menarini to commercialize obicetrapib in the majority of European countries, contingent on regulatory approval. In August 2025, the EMA accepted for review Marketing Authorization Applications submitted by Menarini for obicetrapib monotherapy and the fixed-dose combination with ezetimibe, with regulatory decisions anticipated in the second half of 2026. The company plans to pursue FDA approval independently in the United States, relying on third-party manufacturers for supply. A fourth Phase 3 program—PREVAIL, a cardiovascular outcomes trial enrolling at least 9,000 patients—completed enrollment in April 2024 and cannot conclude before the end of 2026 at the earliest, depending on MACE event accrual. The company also commenced a Phase 2a trial evaluating obicetrapib in early Alzheimer's disease patients carrying the ApoE4 variant, with initial data announced in September 2023.
Show full overview
The PREVAIL CVOT constitutes the dominant binary risk in NewAmsterdam Pharma's development timeline. While obicetrapib met its primary endpoints in BROADWAY, BROOKLYN, and TANDEM, PREVAIL must accumulate a specified number of MACE events before the trial concludes—meaning results may extend well beyond the end of 2026 depending on event accrual rates. If PREVAIL produces negative or inconclusive results, regulators may require further trials before granting NDA approval. The company's entire revenue-generating capacity depends on obicetrapib's approval, as it has no other clinical programs approaching commercialization.
See also: Healthcare · Biotechnology
From NewAmsterdam Pharma Company N.V's most recent 10-K filing, extracted June 11, 2026.
Recent developments
updated 2026-06-15Recent Developments — NewAmsterdam Pharma Company N.V
Latest news
- NEWS Monster Beverage, Westrock Coffee, Himax Technologies And Other Big Stocks Moving Higher On Friday — benzinga May 8, 2026 neutral
- NEWS NewAmsterdam Pharma Q1 EPS $(0.40) Beats $(0.47) Estimate, Sales $3.040M Beat $936.364K Estimate — benzinga May 7, 2026 positive
Generated 2026-06-17T09:07:23Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelineobicetrapib10-K Item 1A: 'We are dependent on the success of our only product candidate, obicetrapib, and cannot guarantee that obicetrapib will successfully complete clinical development, receive regulatory approval'
Material Events(8-K, last 90d)
- 2026-04-24Item 5.02MEDIUMLouise Kooij, Chief Accounting Officer, agreed to depart effective August 31, 2026. Separation agreement includes 12 months base salary and pro-rated bonus. No successor named.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
4 floor-breakers·1 ceiling hit
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Quality below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $30.57: Quality below floor (3.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10 and A.R:R 3.7:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 2.20; Below-average business quality; Negative price momentum. Chart setup: Death cross, below all MAs, RSI 24, MACD bearish. Prior stop was $28.43. Score 5.2/10, moderate confidence.
Take-profit target: $43.58 (+42.6% upside). Prior stop was $28.43. Stop-loss: $28.43.
Concentration risk — Pipeline: obicetrapib; Quality below floor (3.4 < 4.0).
NewAmsterdam Pharma Company N.V trades at a P/E of N/A (forward -23.7). TrendMatrix value score: 9.0/10. Verdict: Sell.
22 analysts cover NAMS with a consensus score of 4.3/5. Average price target: $50.
What does NewAmsterdam Pharma Company N.V do?NewAmsterdam Pharma is a clinical-stage biopharmaceutical company developing obicetrapib, an oral CETP inhibitor for...
NewAmsterdam Pharma is a clinical-stage biopharmaceutical company developing obicetrapib, an oral CETP inhibitor for LDL-C lowering in cardiovascular disease patients. The company has no approved products and generates no product revenue; it is funded through equity and operates at a net loss ($203.8M in 2025).